CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 11 enrolled
Drug / intervention
Oxytocin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02546570
NCT02546570Phase 2Completed
CompareCT.gov

Posttraumatic Stress Disorder and Affective Functioning: A Test of the Potentially Normalizing Effects of Oxytocin

Yale University·interventional·Posted Sep 11, 2015·Updated Apr 8, 2020

In Brief

A Phase 2 clinical trial evaluating Oxytocin and Placebo for Posttraumatic Stress Disorder (PTSD). Completed, enrolled 11 participants across 1 site.

Detailed Summary

The investigators will use multiple methods (including Oxytocin intranasal inhalation, neuroimaging, behavioral measures, peripheral hormone measurements) to examine how individuals' behavior, cognition, and brain function is impacted by the neuro-hormone Oxytocin. Specifically, the investigators plan to evaluate the influence of Oxytocin administration on affective processing in non-trauma exposed and trauma-exposed adults (both with and without posttraumatic stress disorder, PTSD).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPosttraumatic Stress Disorder (PTSD)
CountriesUnited States
CollaboratorsNational Center for PTSD

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedSep 11, 2015
Enrollment StartAug 1, 2015
Primary CompletionAug 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 10.8 years ago

Interventions

Oxytocindrug

See arm/group descriptions for dosage amount and procedure.

Placebodrug

See arm/group descriptions for dosage amount and procedure.